Updated Jul 16, 2026
Hoitt Jason is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $119K.
Jason Hoitt is associated with Stoke Therapeutics, Inc., a biotechnology company focused on developing RNA-targeted medicines for genetic diseases. Specific details about his role and contributions to the company are limited in publicly available sources.
| Role | Insider |
|---|---|
| Notability | 10/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-19 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale | 30 | $32.85 | $986 |
| 2026-03-19 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale | 139 | $31.79 | $4K |
| 2026-03-19 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale | 1.8K | $31.28 | $55K |
| 2026-03-19 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale | 748 | $33.38 | $25K |
| 2026-03-19 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale | 1.0K | $32.74 | $34K |
| 2026-03-17 | STOK | Stoke Therapeutics, Inc. | M — Option exercise | 10.0K | $0.00 |
Jason Hoitt is associated with Stoke Therapeutics, Inc., a biotechnology company focused on developing RNA-targeted medicines for genetic diseases. Specific details about his role and contributions to the company are limited in publicly available sources.…
Recorded transactions: 0 open-market purchases () and 5 open-market sales ($119K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Hoitt Jason profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.